NASDAQ
13.07.26 | 21:59
28,070 US-Dollar
-0,04 % -0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 02.07. | Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination | 24 | Insider Monkey | ||
| 12.06. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | Arcus Biosciences In Clinical Trial Collaboration With Bristol Myers Squibb For Renal Cell Carcinoma | 443 | AFX News | NEW YORK CITY (dpa-AFX) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Wednesday a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY).Under... ► Artikel lesen | |
| 18.05. | Truist assumes Arcus Biosciences stock with buy on RCC potential | 2 | Investing.com | ||
| 11.05. | Arcus Biosciences verfehlt Prognosen für Q1 2026 - Aktie gibt nach | 1 | Investing.com Deutsch | ||
| 05.05. | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 22.04. | What's Going On With Arcus Biosciences Stock On Wednesday? | 4 | Benzinga.com | ||
| 22.04. | Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last? | 1 | Zacks | ||
| 21.04. | Arcus Biosciences: BofA bestätigt "Neutral"-Rating nach Studiendaten von Konkurrent Merck | 6 | Investing.com Deutsch | ||
| 21.04. | Arcus Biosciences stock rating held at Neutral by BofA on rival trial data | 2 | Investing.com | ||
| 20.04. | Leerink senkt Kursziel für Arcus Biosciences nach Ende der Gilead-Kooperation | 19 | Investing.com Deutsch | ||
| 20.04. | Leerink cuts Arcus Biosciences stock price target on Gilead collaboration end | 2 | Investing.com | ||
| 20.04. | Mizuho reiterates Arcus Biosciences stock rating after trial halt | 3 | Investing.com | ||
| 20.04. | Arcus Biosciences: Aktie bricht nach Stopp von Lungenkrebsstudie ein | 2 | Investing.com Deutsch | ||
| 20.04. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.03. | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.02. | Arcus Biosciences: Gewinn pro Aktie übertrifft Erwartungen, Umsatz verfehlt Prognose im 4. Quartal 2025 | - | Investing.com Deutsch | ||
| 25.02. | Arcus Biosciences GAAP EPS of -$0.89 beats by $0.14, revenue of $33M beats by $8.06M | 1 | Seeking Alpha | ||
| 25.02. | Arcus Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.02. | Arcus Biosciences Earnings Review: Q4 Summary | 2 | Benzinga.com |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 23,640 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 41,270 | 0,00 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| EVOTEC | 3,528 | -28,61 % | Evotec-Aktie: Geht die Seitwärtsbewegung weiter? | Die Evotec-Aktie bewegt sich seit mehreren Wochen in einer engen Handelsspanne um die Marke von 5 €. Weder den Bullen noch den Bären ist bislang ein nachhaltiger Ausbruch gelungen. Am Mittwoch notiert... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 110,55 | +0,14 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,34 | -0,07 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| BEAM THERAPEUTICS | 30,990 | -0,03 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| TANGO THERAPEUTICS | 28,350 | -0,04 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,480 | +0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,505 | +0,01 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,79 | -0,02 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| CG ONCOLOGY | 72,55 | +0,07 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| TREVI THERAPEUTICS | 16,515 | -0,03 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,295 | -0,15 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,300 | 0,00 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| TARSUS PHARMACEUTICALS | 59,28 | -0,06 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen |
Das Unternehmen ARCUS BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 28,070 Euro und damit -0,04 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARCUS BIOSCIENCES INC finden Sie auf Wallstreet Online.